{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:31:53Z","timestamp":1788517913075,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clgc.2024.102099","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T01:40:47Z","timestamp":1713922847000},"page":"102099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)"],"prefix":"10.1016","volume":"22","author":[{"given":"Elisabetta","family":"Gambale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-9249","authenticated-orcid":false,"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-1419","authenticated-orcid":false,"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"De Gennaro Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Cavasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-3295","authenticated-orcid":false,"given":"Alessia","family":"Mennitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0546-6304","authenticated-orcid":false,"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3158","authenticated-orcid":false,"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-0567","authenticated-orcid":false,"given":"Martina","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-7755","authenticated-orcid":false,"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-672X","authenticated-orcid":false,"given":"Federico","family":"Scolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6008-0266","authenticated-orcid":false,"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rametta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0001","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.clgc.2024.102099_bib0002","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102099_bib0003","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CCO.0000000000000177","article-title":"Emerging immunotherapies for bladder cancer","volume":"27","author":"Kim","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2024.102099_bib0004","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102099_bib0005","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.clgc.2024.102099_bib0006","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"45","key":"10.1016\/j.clgc.2024.102099_bib0007","doi-asserted-by":"crossref","first-page":"79809","DOI":"10.18632\/oncotarget.19748","article-title":"Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma","volume":"8","author":"Ferrucci","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clgc.2024.102099_bib0008","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/pcmr.13109","article-title":"Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy","volume":"36","author":"Pozorski","year":"2023","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0009","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40425-018-0425-8","article-title":"Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab","volume":"6","author":"Zahoor","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-021-00334-4","article-title":"Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma","volume":"9","author":"Tucker","year":"2021","journal-title":"Biomarker Res"},{"issue":"5","key":"10.1016\/j.clgc.2024.102099_bib0011","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.21037\/jtd-20-3525","article-title":"Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy","volume":"13","author":"Alves","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.clgc.2024.102099_bib0012","article-title":"Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy","volume":"32","author":"Caliman","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.clgc.2024.102099_bib0013","doi-asserted-by":"crossref","first-page":"FSO608","DOI":"10.2144\/fsoa-2020-0070","article-title":"A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy","volume":"6","author":"Krishnan","year":"2020","journal-title":"Future Sci OA"},{"issue":"5","key":"10.1016\/j.clgc.2024.102099_bib0014","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","article-title":"Opposing roles of eosinophils in cancer","volume":"68","author":"Simon","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","article-title":"Eosinophils and cancer","volume":"2","author":"Davis","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.clgc.2024.102099_bib0016","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF01629431","article-title":"Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells","volume":"118","author":"Huland","year":"1992","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102099_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102099_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003302","article-title":"Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival","volume":"10","author":"Manitz","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2024.102099_bib0019","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https:\/\/www.R-project.org\/2023. Accessed April 19, 2023."},{"key":"10.1016\/j.clgc.2024.102099_bib0020","unstructured":"Therneau T. A package for survival analysis in R. R package version 3.5-7, Available at: https:\/\/CRAN.R-project.org\/package=survival;; 2023. Accessed April 19, 2023."},{"key":"10.1016\/j.clgc.2024.102099_bib0021","unstructured":"Wickham H, Fran\u00e7ois R, Henry L, et al. dplyr: a grammar of data manipulation. R package version 1.1.4, Available at: https:\/\/CRAN.R-project.org\/package=dplyr; 2023. Accessed April 19, 2023."},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0022","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","article-title":"Eosinophils in the tumor microenvironment: implications for cancer immunotherapy","volume":"21","author":"Ghaffari","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2024.102099_bib0024","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/2326-6066.CIR-19-1024","article-title":"Tumor-derived IL33 promotes tissue-resident CD8+ T cells and is required for checkpoint blockade tumor immunotherapy","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2024.102099_bib0025","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-020-02522-x","article-title":"Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8+ T cells and enhancing regulatory T cells","volume":"69","author":"Jevtovic","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.clgc.2024.102099_bib0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/oncolo\/oyac236","article-title":"Baseline neutrophil-to-eosinophil ratio is associated with outcomes in metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"28","author":"Zhuang","year":"2023","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.clgc.2024.102099_bib0027","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.4049\/jimmunol.1000446","article-title":"Human eosinophils exert TNF-\u03b1 and granzyme A-mediated tumoricidal activity toward colon carcinoma cells","volume":"185","author":"Legrand","year":"2010","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102099_bib0028","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/gtc.12371","article-title":"CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis","volume":"21","author":"Xing","year":"2016","journal-title":"Genes Cells"},{"issue":"2","key":"10.1016\/j.clgc.2024.102099_bib0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"issue":"17","key":"10.1016\/j.clgc.2024.102099_bib0030","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.3390\/cancers13174247","article-title":"The role of post-translational modifications of chemokines by CD26 in cancer","volume":"13","author":"De Zutter","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2024.102099_bib0031","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.2147\/CMAR.S333823","article-title":"The association of clinical outcomes with posttreatment changes in the relative eosinophil counts and neutrophil-to-eosinophil ratio in patients with advanced urothelial carcinoma treated with pembrolizumab","volume":"13","author":"Furubayashi","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0032","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40425-018-0425-8","article-title":"Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab","volume":"6","author":"Zahoor","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102099_bib0033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/1078-0432.CCR-21-1688","article-title":"Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase III JAVELIN renal 101 trial","volume":"28","author":"Bilen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.102099_bib0034","article-title":"Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102099_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102099_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajur.2015.09.004","article-title":"Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy","volume":"3","author":"Baum","year":"2016","journal-title":"Asian J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102099_bib0037","first-page":"90","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy","volume":"76","author":"Zattoni","year":"2023","journal-title":"Cent European J Urol"},{"key":"10.1016\/j.clgc.2024.102099_bib0038","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8345286","article-title":"Systemic inflammatory response based on neutrophil-to-lymphocyte ratio as a prognostic marker in bladder cancer","volume":"2016","author":"Kim","year":"2016","journal-title":"Dis Markers"},{"issue":"suppl_4","key":"10.1016\/j.clgc.2024.102099_bib0039","first-page":"S1556","article-title":"EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102099_bib0040","unstructured":"FDA approved drug. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer. Accessed December 20, 2023."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T08:32:54Z","timestamp":1718526774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1558767324000703"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102099","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102099"}}